- European regulators recommend rejection of Merck’s Covid-19 drug molnupiravirTerminal News
- European CHMP advises against authorization of Merck’s LagevrioFiercePharma
- Merck and Ridgeback Biotherapeutics to appeal advisory panel against EU regulator’s decision to recommend denying authorization of their COVID antiviralMarketWatch
- EU regulator advises against approval of Merck’s COVID pill for adultsReuters
- Merck/Ridgeback COVID-19 pill rejected in Europe (NYSE: MRK)Looking for Alpha
- See full coverage on Google News